$CVS
CVS HEALTH Corp

2020 Q2 Form 10-Q Financial Statement

#000006480320000030 Filed on August 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q4 2019 Q2
Revenue $65.34B $66.89B $63.43B
YoY Change 3.01% 22.9% 35.18%
Cost Of Revenue $40.24B $42.07B $38.97B
YoY Change 3.26% 10.22% 0.24%
Gross Profit $25.10B $24.82B $24.46B
YoY Change 2.61% 48.26% 204.01%
Gross Profit Margin 38.41% 37.11% 38.56%
Selling, General & Admin $8.598B $8.394B $7.975B
YoY Change 7.81% 26.93% 63.86%
% of Gross Profit 34.26% 33.81% 32.6%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $8.668B $21.53B $8.042B
YoY Change 7.78% 63.0% 65.24%
Operating Profit $4.680B $3.037B $3.332B
YoY Change 40.46% 268.57% -342.68%
Interest Expense $765.0M -$734.0M $772.0M
YoY Change -0.91% -39.74% 12.05%
% of Operating Profit 16.35% -24.17% 23.17%
Other Income/Expense, Net $45.00M $31.00M $31.00M
YoY Change 45.16% 181.82% -1133.33%
Pretax Income $3.960B $2.334B $2.591B
YoY Change 52.84% 2188.24% -225.47%
Income Tax $974.0M $590.0M $660.0M
% Of Pretax Income 24.6% 25.28% 25.47%
Net Earnings $2.975B $1.747B $1.936B
YoY Change 53.67% -516.95% -175.54%
Net Earnings / Revenue 4.55% 2.61% 3.05%
Basic Earnings Per Share $2.27 $1.34 $1.49
Diluted Earnings Per Share $2.26 $1.33 $1.49
COMMON SHARES
Basic Shares Outstanding 1.309B shares 1.301B shares 1.301B shares
Diluted Shares Outstanding 1.314B shares 1.302B shares

Balance Sheet

Concept 2020 Q2 2019 Q4 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.47B $8.056B $8.525B
YoY Change 104.87% 25.52% -80.59%
Cash & Equivalents $14.87B $5.683B $6.063B
Short-Term Investments $2.596B $2.373B $2.462B
Other Short-Term Assets $6.002B $5.113B $4.691B
YoY Change 27.95% 11.61% 487.11%
Inventory $16.52B $17.52B $15.51B
Prepaid Expenses
Receivables $22.52B $19.62B $18.17B
Other Receivables $2.801B $2.381B $752.0M
Total Short-Term Assets $62.51B $50.30B $46.90B
YoY Change 33.27% 11.18% -36.44%
LONG-TERM ASSETS
Property, Plant & Equipment $12.22B $12.04B $11.48B
YoY Change 6.43% 6.12% 12.04%
Goodwill $80.06B $79.75B $79.49B
YoY Change 0.72% 1.36%
Intangibles $32.23B $33.12B $34.16B
YoY Change -5.67% -9.32%
Long-Term Investments $18.59B $17.31B $16.97B
YoY Change 9.55% 10.06%
Other Assets $4.682B $4.600B $4.763B
YoY Change -1.7% -8.84% 178.7%
Total Long-Term Assets $173.0B $172.1B $172.0B
YoY Change 0.57% 13.84% 189.08%
TOTAL ASSETS
Total Short-Term Assets $62.51B $50.30B $46.90B
Total Long-Term Assets $173.0B $172.1B $172.0B
Total Assets $235.5B $222.4B $218.9B
YoY Change 7.58% 13.23% 64.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $32.82B $30.97B $27.99B
YoY Change 17.28% 17.15% 37.77%
Accrued Expenses $15.63B $12.13B $10.56B
YoY Change 48.02% 13.28% 38.25%
Deferred Revenue $78.00M $73.00M $76.00M
YoY Change 2.63% 8.96%
Short-Term Debt $0.00 $0.00 $446.0M
YoY Change -100.0% -100.0%
Long-Term Debt Due $8.192B $3.781B $3.894B
YoY Change 110.37% 198.89% 10.0%
Total Short-Term Liabilities $63.69B $53.30B $49.38B
YoY Change 29.0% 21.12% 56.78%
LONG-TERM LIABILITIES
Long-Term Debt $63.48B $64.70B $66.94B
YoY Change -5.17% -9.44% 8.73%
Other Long-Term Liabilities $2.308B $2.162B $2.528B
YoY Change -8.7% -22.23% 61.74%
Total Long-Term Liabilities $65.79B $66.86B $69.47B
YoY Change -5.3% -9.92% 10.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $63.69B $53.30B $49.38B
Total Long-Term Liabilities $65.79B $66.86B $69.47B
Total Liabilities $167.1B $158.3B $157.3B
YoY Change 6.25% 14.77% 61.04%
SHAREHOLDERS EQUITY
Retained Earnings $48.77B $45.11B $43.14B
YoY Change 13.06% 10.26%
Common Stock $17.00M $17.00M $17.00M
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $28.24B $28.24B $28.26B
YoY Change -0.08% 0.02%
Treasury Stock Shares 425.0M shares 425.0M shares 425.0M shares
Shareholders Equity $68.02B $63.86B $61.28B
YoY Change
Total Liabilities & Shareholders Equity $235.5B $222.4B $218.9B
YoY Change 7.58% 13.23% 64.23%

Cashflow Statement

Concept 2020 Q2 2019 Q4 2019 Q2
OPERATING ACTIVITIES
Net Income $2.975B $1.747B $1.936B
YoY Change 53.67% -516.95% -175.54%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $7.119B $2.634B $5.338B
YoY Change 33.36% 6.25% 81.94%
INVESTING ACTIVITIES
Capital Expenditures -$448.0M -$567.0M -$573.0M
YoY Change -21.82% -3.08% 33.26%
Acquisitions
YoY Change
Other Investing Activities -$885.0M -$142.0M -$337.0M
YoY Change 162.61% -99.66% 76.44%
Cash From Investing Activities -$1.333B -$709.0M -$910.0M
YoY Change 46.48% -98.31% 46.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -978.0M -1.440B -4.258B
YoY Change -77.03% -176.11% 718.85%
NET CHANGE
Cash From Operating Activities 7.119B 2.634B 5.338B
Cash From Investing Activities -1.333B -709.0M -910.0M
Cash From Financing Activities -978.0M -1.440B -4.258B
Net Change In Cash 4.808B 485.0M 170.0M
YoY Change 2728.24% -101.29% -90.52%
FREE CASH FLOW
Cash From Operating Activities $7.119B $2.634B $5.338B
Capital Expenditures -$448.0M -$567.0M -$573.0M
Free Cash Flow $7.567B $3.201B $5.911B
YoY Change 28.02% 4.47% 75.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2019Q1 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2019Q4 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2020Q1 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2018Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2019Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2019Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2020Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2019Q2 us-gaap Revenues
Revenues
63431000000 USD
us-gaap Revenues
Revenues
132096000000 USD
us-gaap Revenues
Revenues
125077000000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
40242000000 USD
dei Entity Central Index Key
EntityCentralIndexKey
0000064803
us-gaap Net Income Loss
NetIncomeLoss
4982000000 USD
CY2018 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201602Member
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
38970000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
80589000000 USD
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201613Member
us-gaap Change In Accounting Principle Accounting Standards Update Transition Option Elected Extensible List
ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList
cvs:AccountingStandardsUpdate201613ModifiedRetrospectiveMember
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1727000000 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1732000000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1302000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1307000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000.0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
76217000000 USD
CY2020Q2 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
11751000000 USD
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q2 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
13087000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
32073000000 USD
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
425000000 shares
CY2020Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
425000000 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-01011
dei Entity Registrant Name
EntityRegistrantName
CVS HEALTH CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
05-0494040
dei Entity Address Address Line1
EntityAddressAddressLine1
One CVS Drive,
dei Entity Address City Or Town
EntityAddressCityOrTown
Woonsocket,
dei Entity Address State Or Province
EntityAddressStateOrProvince
RI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02895
dei City Area Code
CityAreaCode
(401)
dei Local Phone Number
LocalPhoneNumber
765-1500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
CVS
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
26138000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
346000000 USD
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
26546000000 USD
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000.0 shares
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1308703450 shares
CY2020Q2 us-gaap Premiums Earned Net
PremiumsEarnedNet
16927000000 USD
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q2 us-gaap Premiums Earned Net
PremiumsEarnedNet
15791000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
34567000000 USD
CY2020Q2 us-gaap Net Investment Income
NetInvestmentIncome
184000000 USD
CY2019Q2 us-gaap Net Investment Income
NetInvestmentIncome
293000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
542000000 USD
CY2020Q2 us-gaap Revenues
Revenues
65341000000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
8668000000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
8042000000 USD
us-gaap Operating Expenses
OperatingExpenses
17231000000 USD
us-gaap Operating Expenses
OperatingExpenses
16292000000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
60661000000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
60099000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
123958000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
119055000000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
4680000000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3332000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
8138000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
6022000000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
765000000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
772000000 USD
us-gaap Interest Expense
InterestExpense
1498000000 USD
us-gaap Interest Expense
InterestExpense
1554000000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
45000000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
99000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
62000000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3960000000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2591000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
6739000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
4530000000 USD
us-gaap Profit Loss
ProfitLoss
4998000000 USD
us-gaap Net Income Loss
NetIncomeLoss
3357000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1172000000 USD
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.27
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
974000000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
660000000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
2986000000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
1931000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1741000000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
2975000000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
1936000000 USD
us-gaap Profit Loss
ProfitLoss
3358000000 USD
CY2020Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000 USD
CY2019Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
16000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1000000 USD
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.58
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.26
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.58
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1309000000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1301000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1307000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1299000000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1314000000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1302000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1313000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1302000000 shares
CY2020Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
CY2019Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.00
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.00
CY2020Q2 us-gaap Profit Loss
ProfitLoss
2986000000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
1931000000 USD
us-gaap Profit Loss
ProfitLoss
4998000000 USD
us-gaap Profit Loss
ProfitLoss
3358000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
524000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
251000000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
213000000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
585000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20860000000 USD
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
1000000 USD
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6000000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-3000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-3000000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-12000000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-7000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
1000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
526000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
251000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
194000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
582000000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
3512000000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
2182000000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
5192000000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
3940000000 USD
CY2020Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000 USD
CY2019Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
16000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1000000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3501000000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2187000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5176000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3939000000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14869000000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5683000000 USD
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
2596000000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
2373000000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22520000000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19617000000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
16519000000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
17516000000 USD
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
6002000000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5113000000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
62506000000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
50302000000 USD
CY2020Q2 us-gaap Long Term Investments
LongTermInvestments
18594000000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
79749000000 USD
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
32225000000 USD
CY2020Q2 us-gaap Assets
Assets
235495000000 USD
CY2020Q2 us-gaap Goodwill
Goodwill
80057000000 USD
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
17314000000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12221000000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12044000000 USD
CY2019Q4 us-gaap Assets
Assets
222449000000 USD
CY2020Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
9919000000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20571000000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
33121000000 USD
CY2020Q2 us-gaap Separate Account Assets
SeparateAccountAssets
4639000000 USD
CY2019Q4 us-gaap Separate Account Assets
SeparateAccountAssets
4459000000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4682000000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4600000000 USD
CY2019Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
10492000000 USD
CY2020Q2 cvs Pharmacy Claimsand Discounts Payable Current
PharmacyClaimsandDiscountsPayableCurrent
15541000000 USD
CY2019Q4 cvs Pharmacy Claimsand Discounts Payable Current
PharmacyClaimsandDiscountsPayableCurrent
13601000000 USD
CY2020Q2 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
7362000000 USD
CY2019Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
6879000000 USD
CY2020Q2 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
3636000000 USD
CY2019Q4 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
2991000000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15634000000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12133000000 USD
CY2020Q2 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1644000000 USD
CY2019Q4 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1830000000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1766000000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1596000000 USD
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
8192000000 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3781000000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
63694000000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53303000000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18612000000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18926000000 USD
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
63481000000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
64699000000 USD
CY2020Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7136000000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7294000000 USD
CY2020Q2 us-gaap Separate Accounts Liability
SeparateAccountsLiability
4639000000 USD
CY2019Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
4459000000 USD
CY2020Q2 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
7270000000 USD
CY2019Q4 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
7436000000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2308000000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2162000000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
167140000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1289000000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
48768000000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
3946000000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
768000000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
158279000000 USD
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
46276000000 USD
CY2019Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
45972000000 USD
CY2020Q2 us-gaap Treasury Stock Value
TreasuryStockValue
28235000000 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
28235000000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
45108000000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1213000000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1019000000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
68022000000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
63864000000 USD
CY2020Q2 us-gaap Minority Interest
MinorityInterest
333000000 USD
CY2019Q4 us-gaap Minority Interest
MinorityInterest
306000000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68355000000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
64170000000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
235495000000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
222449000000 USD
us-gaap Proceeds From Customers
ProceedsFromCustomers
129218000000 USD
us-gaap Proceeds From Customers
ProceedsFromCustomers
120808000000 USD
cvs Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies
PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies
76381000000 USD
cvs Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies
PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies
70567000000 USD
cvs Paymentsfor Insurance Benefits
PaymentsforInsuranceBenefits
26483000000 USD
cvs Paymentsfor Insurance Benefits
PaymentsforInsuranceBenefits
25992000000 USD
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
14688000000 USD
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
14497000000 USD
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
395000000 USD
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
512000000 USD
us-gaap Interest Paid Net
InterestPaidNet
1407000000 USD
us-gaap Interest Paid Net
InterestPaidNet
1502000000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
230000000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1476000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10424000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7286000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2710000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3786000000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
3688000000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
4062000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1190000000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
250000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-6000000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-14000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2930000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1801000000 USD
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
0 USD
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-275000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1016000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1899000000 USD
us-gaap Payments Of Dividends
PaymentsOfDividends
1315000000 USD
us-gaap Payments Of Dividends
PaymentsOfDividends
1306000000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
166000000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
111000000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
68000000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
80000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-16000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
7000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1697000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3442000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9191000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2043000000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5954000000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4295000000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15145000000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6338000000 USD
us-gaap Profit Loss
ProfitLoss
4998000000 USD
us-gaap Profit Loss
ProfitLoss
3358000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2188000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2183000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
179000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
226000000 USD
cvs Deferredincometaxesandothernoncashitems
Deferredincometaxesandothernoncashitems
-101000000 USD
cvs Deferredincometaxesandothernoncashitems
Deferredincometaxesandothernoncashitems
-42000000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2233000000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
681000000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1003000000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-939000000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
560000000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
314000000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1671000000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
917000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7286000000 USD
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
-415000000 USD
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
496000000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
3694000000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
204000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10424000000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
64170000000 USD
CY2020Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
2012000000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-332000000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
208000000 USD
CY2020Q1 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
-53000000 USD
CY2020Q1 us-gaap Dividends Common Stock
DividendsCommonStock
657000000 USD
CY2020Q1 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
23000000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65474000000 USD
CY2020Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
2986000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
526000000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
96000000 USD
CY2020Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
53000000 USD
CY2020Q2 us-gaap Dividends Common Stock
DividendsCommonStock
662000000 USD
CY2020Q2 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
-12000000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68355000000 USD
CY2020Q2 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2020Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
58543000000 USD
CY2019Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
1427000000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
331000000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
175000000 USD
CY2019Q1 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
-7000000 USD
CY2019Q1 us-gaap Dividends Common Stock
DividendsCommonStock
651000000 USD
CY2019Q1 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
-4000000 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60006000000 USD
CY2019Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
1931000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
251000000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000000 USD
CY2019Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
36000000 USD
CY2019Q2 us-gaap Dividends Common Stock
DividendsCommonStock
659000000 USD
CY2019Q2 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
2000000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
61599000000 USD
CY2019Q2 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2019Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2020Q2 cvs Numberof Pharmacy Plan Members
NumberofPharmacyPlanMembers
103000000 person
CY2020Q2 cvs Numberof Patients Servedper Year
NumberofPatientsServedperYear
1000000 patient
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 Segment
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div>
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14869000000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5683000000 USD
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
276000000 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
271000000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15145000000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5954000000 USD
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
6848000000 USD
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
6717000000 USD
CY2020Q2 cvs Vendorand Manufacturer Receivables
VendorandManufacturerReceivables
9791000000 USD
CY2019Q4 cvs Vendorand Manufacturer Receivables
VendorandManufacturerReceivables
7856000000 USD
CY2020Q2 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
3080000000 USD
CY2019Q4 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
2663000000 USD
CY2020Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2801000000 USD
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2381000000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22520000000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19617000000 USD
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
342000000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
319000000 USD
CY2020Q2 us-gaap Net Investment Income
NetInvestmentIncome
184000000 USD
CY2020Q2 us-gaap Revenues
Revenues
65341000000 USD
CY2019Q2 us-gaap Net Investment Income
NetInvestmentIncome
293000000 USD
CY2019Q2 us-gaap Revenues
Revenues
63431000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
346000000 USD
us-gaap Revenues
Revenues
132096000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
542000000 USD
us-gaap Revenues
Revenues
125077000000 USD
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
6848000000 USD
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
6717000000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
78000000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
73000000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
73000000 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
67000000 USD
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
179000000 USD
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
181000000 USD
cvs Contractwith Customer Liability Redemptionand Breakage
ContractwithCustomerLiabilityRedemptionandBreakage
174000000 USD
cvs Contractwith Customer Liability Redemptionand Breakage
ContractwithCustomerLiabilityRedemptionandBreakage
172000000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
78000000 USD
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
76000000 USD
CY2020Q2 cvs Health Insurer Fee
HealthInsurerFee
248000000 USD
cvs Health Insurer Fee
HealthInsurerFee
519000000 USD
CY2020Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
3000000 USD
CY2019Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
2000000 USD
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
23000000 USD
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
12000000 USD
CY2020Q2 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
22000000 USD
CY2019Q2 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
27000000 USD
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
43000000 USD
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
52000000 USD
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
2596000000 USD
CY2020Q2 us-gaap Long Term Investments
LongTermInvestments
18594000000 USD
CY2020Q2 us-gaap Investments
Investments
21190000000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
2373000000 USD
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
17314000000 USD
CY2019Q4 us-gaap Investments
Investments
19687000000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
17111000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
3000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Amortized Cost Net
DebtSecuritiesAvailableForSaleAmortizedCostNet
17108000000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1499000000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
53000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
18554000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
15898000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2019Q4 cvs Debt Securities Available For Sale Amortized Cost Net
DebtSecuritiesAvailableForSaleAmortizedCostNet
15898000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1035000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
16922000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2020Q2 cvs Debt Securities Available For Sale Maturity Allocated And Single Maturity Date Within One Year Amortized Cost Net
DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNet
1198000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1214000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Five Years Amortized Cost Net
DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAmortizedCostNet
5619000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
5925000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Maturity Allocated And Single Maturity Dateafter Five Through Ten Years Amortized Cost Net
DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateafterFiveThroughTenYearsAmortizedCostNet
3160000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
3448000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Allocated And Single Maturity Date Maturity After10 Years Amortized Cost Net
DebtSecuritiesAvailableForSaleAllocatedAndSingleMaturityDateMaturityAfter10YearsAmortizedCostNet
3897000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
4620000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Amortized Cost Net
DebtSecuritiesAvailableForSaleAmortizedCostNet
17108000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
18554000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
1279 security
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1684000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
46000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
109 security
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
84000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
7000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
1388 security
CY2020Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
1768000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
53000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
522 security
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
982000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
6000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
200 security
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
187000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
5000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
722 security
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
1169000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
11000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
48000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss
0 USD
CY2020Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears
370000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss
9000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears
326000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
12000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
259000000 USD
CY2020Q2 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
10000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
1768000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
53000000 USD
CY2020Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
141000000 USD
CY2019Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
231000000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
347000000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
430000000 USD
CY2020Q2 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
9000000 USD
CY2019Q2 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
9000000 USD
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
17000000 USD
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
18000000 USD
CY2020Q2 cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
132000000 USD
CY2019Q2 cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
222000000 USD
cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
330000000 USD
cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
412000000 USD
CY2020Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
52000000 USD
CY2019Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
71000000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
16000000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
130000000 USD
CY2020Q2 us-gaap Investment Income Net
InvestmentIncomeNet
184000000 USD
CY2019Q2 us-gaap Investment Income Net
InvestmentIncomeNet
293000000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
346000000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
542000000 USD
CY2020Q2 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
-42000000 USD
CY2020Q2 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
1000000 USD
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
3000000 USD
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
42000000 USD
CY2019Q2 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
6000000 USD
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
13000000 USD
CY2020Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1419000000 USD
CY2019Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1273000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2142000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2762000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
23000000 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
37000000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
43000000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
72000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
21000000 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
2000000 USD
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
56000000 USD
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
4000000 USD
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">The following table shows the components of the change in health care costs payable during the </span><span style="font-family:Times New Roman;font-size:10pt;">six months ended</span><span style="font-family:Times New Roman;font-size:10pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;">June 30, 2020</span><span style="font-family:Times New Roman;font-size:10pt;"> and 2019:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;text-decoration:underline;">In millions</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Health care costs payable, beginning of the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,879</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Reinsurance recoverables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Health care costs payable, beginning of the period, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add: Components of incurred health care costs</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,864</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(420</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total incurred health care costs </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Claims paid</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,552</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,095</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total claims paid</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,927</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add: Premium deficiency reserve</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Health care costs payable, end of the period, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,358</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,885</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Add: Reinsurance recoverables</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Health care costs payable, end of the period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,362</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,889</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">_____________________________________________</sup> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;vertical-align:bottom;font-size:8pt;padding-left:0px;"><span style="font-family:Times New Roman;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;vertical-align:bottom;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;">Total incurred health care costs for the </span><span style="font-family:Times New Roman;font-size:8pt;">six months ended</span><span style="font-family:Times New Roman;font-size:8pt;"> </span><span style="font-family:Times New Roman;font-size:8pt;">June 30, 2020</span><span style="font-family:Times New Roman;font-size:8pt;"> and </span><span style="font-family:Times New Roman;font-size:8pt;">2019</span><span style="font-family:Times New Roman;font-size:8pt;"> in the table above exclude (i) </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$29 million</span></span><span style="font-family:Times New Roman;font-size:8pt;"> and </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$14 million</span></span><span style="font-family:Times New Roman;font-size:8pt;">, respectively, related to a premium deficiency reserve related to the Company’s Medicaid products, (ii) </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$20 million</span></span><span style="font-family:Times New Roman;font-size:8pt;"> and </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$21 million</span></span><span style="font-family:Times New Roman;font-size:8pt;">, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the Company’s unaudited condensed consolidated balance sheets and (iii) </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$119 million</span></span><span style="font-family:Times New Roman;font-size:8pt;"> and </span><span style="font-family:Times New Roman;font-size:8pt;"><span>$136 million</span></span><span style="font-family:Times New Roman;font-size:8pt;">, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the Company’s unaudited condensed consolidated balance sheets.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div>
CY2020Q2 us-gaap Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net
ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
5400000000 USD
CY2020Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
1002000000 USD
CY2019Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
808000000 USD
CY2020Q2 cvs Longterm Debt Gross And Lease Obligation
LongtermDebtGrossAndLeaseObligation
72438000000 USD
CY2019Q4 cvs Longterm Debt Gross And Lease Obligation
LongtermDebtGrossAndLeaseObligation
69246000000 USD
CY2020Q2 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
251000000 USD
CY2019Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
262000000 USD
CY2020Q2 cvs Debt Instrument Unamortized Discountand Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet
1016000000 USD
CY2019Q4 cvs Debt Instrument Unamortized Discountand Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet
1028000000 USD
CY2020Q2 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
71673000000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
68480000000 USD
CY2020Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
8192000000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
3781000000 USD
CY2020Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
63481000000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
64699000000 USD
CY2020Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
3950000000 USD
CY2020Q1 us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
7000000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-5000000 USD
CY2020Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.00
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
526000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
251000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
194000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
582000000 USD
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15000000 shares
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19000000 shares
CY2020Q2 us-gaap Profit Loss
ProfitLoss
2986000000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
1931000000 USD
us-gaap Profit Loss
ProfitLoss
4998000000 USD
us-gaap Profit Loss
ProfitLoss
3358000000 USD
CY2020Q2 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 USD
CY2019Q2 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
1000000 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
3000000 USD
CY2020Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000 USD
CY2019Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
16000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1000000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2975000000 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1935000000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4982000000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3354000000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1309000000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1301000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1307000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1299000000 shares
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
5000000 shares
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1000000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
6000000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3000000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1314000000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1302000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1313000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1302000000 shares
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.27
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.58
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.26
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.58
CY2020Q2 cvs Guarantor Obligations Numberof Leases
GuarantorObligationsNumberofLeases
76 store
CY2015Q3 cvs Loss Contingency Number Of Locations With Subpoena For Documents
LossContingencyNumberOfLocationsWithSubpoenaForDocuments
8 store
CY2012 cvs Loss Contingency Audit Methodology Sample Size
LossContingencyAuditMethodologySampleSize
200 member
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
6 claim
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
6 claim
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 Segment
CY2020Q2 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
65157000000 USD
CY2020Q2 us-gaap Net Investment Income
NetInvestmentIncome
184000000 USD
CY2020Q2 us-gaap Revenues
Revenues
65341000000 USD
CY2020Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
5328000000 USD
CY2019Q2 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
63138000000 USD
CY2019Q2 us-gaap Net Investment Income
NetInvestmentIncome
293000000 USD
CY2019Q2 us-gaap Revenues
Revenues
63431000000 USD
CY2019Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4031000000 USD
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
131750000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
346000000 USD
us-gaap Revenues
Revenues
132096000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
9441000000 USD
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
124535000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
542000000 USD
us-gaap Revenues
Revenues
125077000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
7626000000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
4680000000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3332000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
8138000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
6022000000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
578000000 USD
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
593000000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1164000000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1215000000 USD
CY2020Q2 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
70000000 USD
CY2019Q2 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
106000000 USD
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
139000000 USD
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
254000000 USD
CY2020Q2 cvs Store Rationalization Charges
StoreRationalizationCharges
0 USD
CY2019Q2 cvs Store Rationalization Charges
StoreRationalizationCharges
0 USD
cvs Store Rationalization Charges
StoreRationalizationCharges
0 USD
cvs Store Rationalization Charges
StoreRationalizationCharges
135000000 USD
CY2020Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
5328000000 USD
CY2019Q2 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
4031000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
9441000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
7626000000 USD

Files In Submission

Name View Source Status
0000064803-20-000030-index-headers.html Edgar Link pending
0000064803-20-000030-index.html Edgar Link pending
0000064803-20-000030.txt Edgar Link pending
0000064803-20-000030-xbrl.zip Edgar Link pending
a0630202010-q.htm Edgar Link pending
a0630202010-q_htm.xml Edgar Link completed
a06302020ex101.htm Edgar Link pending
a06302020ex151.htm Edgar Link pending
a06302020ex311.htm Edgar Link pending
a06302020ex312.htm Edgar Link pending
a06302020ex321.htm Edgar Link pending
a06302020ex322.htm Edgar Link pending
cvs-20200630.xsd Edgar Link pending
cvs-20200630_cal.xml Edgar Link unprocessable
cvs-20200630_def.xml Edgar Link unprocessable
cvs-20200630_lab.xml Edgar Link unprocessable
cvs-20200630_pre.xml Edgar Link unprocessable
cvshealtha39.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending